Pleural InfectionTORPIDS-3NCT07194915
Pleural Fluid Neutrophil Extracellular Traps Exacerbate Disease Severity and Risk of One-year Mortality in Pleural Infection (TORPIDS-3)
An observational study of Pleural Infection, run by University of Oxford at 1 site in United Kingdom.
Trial summary
Pleural infection is a severe and complicated disease which is associated with significant morbidity and mortality. People with pleural infection show diverse levels of neutrophil degranulation activity. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Pleural Infection
- How many people
- 326 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 9 Jan 2024to 1 Oct 2025
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients with confirmed pleural infection
Who may be able to join
- Patients were included if they had a clinical presentation consistent with pleural infection as stated in the Methods section of the main manuscript and any of the following criteria:
- Pleural fluid that was macroscopically purulent, OR
- Pleural fluid that was positive on culture for bacterial infection, OR
- Pleural fluid that demonstrated bacteria on Gram staining, OR
- Pleural fluid with pH ≤7.2 (measured in a blood gas analyser) or low glucose level (≤3mmol/L or ≤55mg/dL) in a patient with clinical evidence of infection, OR
- Contrast-enhanced CT evidence of pleural infection (consolidation of underlying lung with enhancing pleural collection) in a patient with clinical evidence of infection, alongside exclusion of other sources of infection.
Who cannot join
- Age less than 18 years, OR
- No pleural fluid available for analysis, OR
- Patient previous pneumonectomy on the side of pleural infection, OR
- Expected survival less than three months due to co-morbid disease, as judged by the recruiting physician
Trial locations and contacts
1 site in 1 country.
United Kingdom1 site
CAMS Oxford Institute, Nuffield Department of Medicine
Oxford
About this study
Official title: Pleural Fluid Neutrophil Extracellular Traps Exacerbate Disease Severity and Risk of One-year Mortality in Pleural Infection: An Observational, International, Multicohort Study (TORPIDS-3)
Pleural infection is a severe and complicated disease which is associated with significant morbidity and mortality. People with pleural infection show diverse levels of neutrophil degranulation activity. The investigators examined the biological role of pleural fluid neutrophil extracellular traps in patients with pleural infection. TORPIDS-3 is an observational, International multicohort study.
- Conditions
- Pleural Infection
- Keywords
- pleural infection, neutrophils, neutrophil extracellular traps, NETs, inflammation
- Medical subject headings
- Inflammation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| PILOT | Pleural fluid specimens collected for the PILOT study | |
| Oxford Pleural Biobank | Pleural fluid specimens collected in Oxford | |
| Oxford-Osler | Pleural fluid specimens collected in Oxford | |
| Patras Pleural Biobank | Pleural fluid specimens collected in Patras, Greece | |
| Ancona Pleural Biobank | Pleural fluid specimens collected in Ancona, Italy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Disease severity
Association between pleural fluid NETs with disease severity
Measured: Baseline
One-year mortality
Association between pleural fluid NETs and risk of one-year mortality
Measured: Baseline
Secondary outcomes (3)
Bacterial profiles
Association between pleural fluid NETs with bacterial profiles
Measured: Baseline
Sonographic septations
Association between pleural fluid NETs and the presence of sonographic septations
Measured: Baseline
Need for Intrapleural Enzyme Therapy (IET)
Association between pleural fluid NETs with the requirement for IET
Measured: Baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Sep 2025
- Study start9 Jan 2024
- Primary completion31 Aug 2025
- Study completion1 Oct 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Pleural InfectionStudies of the same condition, open and under way.
- More trials run by University of OxfordThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 326 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Oxford
- Sponsor type
- University, hospital or other
- Collaborators
- University of Dundee
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07194915
- Sponsor's protocol ID
- TORPIDS-3
- Acronym
- TORPIDS-3
- Status last verified
- Sep 2025
- First submitted
- 10 Sep 2025
- Last updated
- 26 Sep 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Kanellakis NI, Antoun E, Cano-Gamez K, Chu J, Manoharan N, Berridge G, Vendrell I, Zhang Z, Corcoran JP, Elsheikh A, Dong T, Fischer R, Whalley JP, Knight JC, Rahman NM. Pleural fluid proteomics from patients with pleural infection shows signatures of diverse neutrophilic responses: The Oxford Pleural Infection Endotyping Study (TORPIDS-2). Eur Respir J. 2025 Jul 14;66(1):2500010. doi: 10.1183/13993003.00010-2025. Print 2025 Jul.
PubMed 40246538Corcoran JP, Psallidas I, Gerry S, Piccolo F, Koegelenberg CF, Saba T, Daneshvar C, Fairbairn I, Heinink R, West A, Stanton AE, Holme J, Kastelik JA, Steer H, Downer NJ, Haris M, Baker EH, Everett CF, Pepperell J, Bewick T, Yarmus L, Maldonado F, Khan B, Hart-Thomas A, Hands G, Warwick G, De Fonseka D, Hassan M, Munavvar M, Guhan A, Shahidi M, Pogson Z, Dowson L, Popowicz ND, Saba J, Ward NR, Hallifax RJ, Dobson M, Shaw R, Hedley EL, Sabia A, Robinson B, Collins GS, Davies HE, Yu LM, Miller RF, Maskell NA, Rahman NM. Prospective validation of the RAPID clinical risk prediction score in adult patients with pleural infection: the PILOT study. Eur Respir J. 2020 Nov 26;56(5):2000130. doi: 10.1183/13993003.00130-2020. Print 2020 Nov.
PubMed 32675200
Study at a glance
From the registry record, last updated by the sponsor on 26 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Pleural Fluid Neutrophil Extracellular Traps Exacerbate Disease Severity and Risk of One-year Mortality in Pleural Infection: An Observational, International, Multicohort Study (TORPIDS-3)
- ClinicalTrials.gov ID
- NCT07194915
- Acronym / sponsor ID
- TORPIDS-3 / TORPIDS-3
- Conditions
- Pleural Infection
- Keywords
- pleural infection, neutrophils, neutrophil extracellular traps, NETs, inflammation
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 326 participants (actual)
- Lead sponsor
- University of OxfordUniversity, hospital or other
- Collaborators
- University of Dundee
- Study start
- 9 Jan 2024 (actual)
- Primary completion
- 31 Aug 2025 (actual)
- Study completion
- 1 Oct 2025 (estimated)
- First posted
- 26 Sep 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Pleural infection is a severe and complicated disease which is associated with significant morbidity and mortality. People with pleural infection show diverse levels of neutrophil degranulation activity. The investigators examined the biological role of pleural fluid neutrophil extracellular traps in patients with pleural infection. TORPIDS-3 is an observational, International multicohort study.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 5
| Arm | Type | Receives |
|---|---|---|
| PILOT | – | –Pleural fluid specimens collected for the PILOT study |
| Oxford Pleural Biobank | – | –Pleural fluid specimens collected in Oxford |
| Oxford-Osler | – | –Pleural fluid specimens collected in Oxford |
| Patras Pleural Biobank | – | –Pleural fluid specimens collected in Patras, Greece |
| Ancona Pleural Biobank | – | –Pleural fluid specimens collected in Ancona, Italy |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients with confirmed pleural infection
Key inclusion criteria (6 listed)
- Patients were included if they had a clinical presentation consistent with pleural infection as stated in the Methods section of the main manuscript and any of the following criteria:
- Pleural fluid that was macroscopically purulent, OR
- Pleural fluid that was positive on culture for bacterial infection, OR
- Pleural fluid that demonstrated bacteria on Gram staining, OR
- Pleural fluid with pH ≤7.2 (measured in a blood gas analyser) or low glucose level (≤3mmol/L or ≤55mg/dL) in a patient with clinical evidence of infection, OR
Key exclusion criteria (4 listed)
- Age less than 18 years, OR
- No pleural fluid available for analysis, OR
- Patient previous pneumonectomy on the side of pleural infection, OR
- Expected survival less than three months due to co-morbid disease, as judged by the recruiting physician
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Disease severity
Time frame: Baseline
Association between pleural fluid NETs with disease severity
One-year mortality
Time frame: Baseline
Association between pleural fluid NETs and risk of one-year mortality
3 secondary outcomes
Bacterial profiles
Time frame: Baseline
Sonographic septations
Time frame: Baseline
Need for Intrapleural Enzyme Therapy (IET)
Time frame: Baseline
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Sep 2025.
- Background: PubMed 40246538Kanellakis NI, Antoun E, Cano-Gamez K, Chu J, Manoharan N, Berridge G, Vendrell I, Zhang Z, Corcoran JP, Elsheikh A, Dong T, Fischer R, Whalley JP, Knight JC, Rahman NM. Pleural fluid proteomics from patients with pleural infection shows signatures of diverse neutrophilic responses: The Oxford Pleural Infection Endotyping Study (TORPIDS-2). Eur Respir J. 2025 Jul 14;66(1):2500010. doi: 10.1183/13993003.00010-2025. Print 2025 Jul.
- Background: PubMed 32675200Corcoran JP, Psallidas I, Gerry S, Piccolo F, Koegelenberg CF, Saba T, Daneshvar C, Fairbairn I, Heinink R, West A, Stanton AE, Holme J, Kastelik JA, Steer H, Downer NJ, Haris M, Baker EH, Everett CF, Pepperell J, Bewick T, Yarmus L, Maldonado F, Khan B, Hart-Thomas A, Hands G, Warwick G, De Fonseka D, Hassan M, Munavvar M, Guhan A, Shahidi M, Pogson Z, Dowson L, Popowicz ND, Saba J, Ward NR, Hallifax RJ, Dobson M, Shaw R, Hedley EL, Sabia A, Robinson B, Collins GS, Davies HE, Yu LM, Miller RF, Maskell NA, Rahman NM. Prospective validation of the RAPID clinical risk prediction score in adult patients with pleural infection: the PILOT study. Eur Respir J. 2020 Nov 26;56(5):2000130. doi: 10.1183/13993003.00130-2020. Print 2020 Nov.
- Individual participant dataSharing planned: No
Related trials for Pleural Infection
Active, not recruitingPhase 1/2
A Beta-only IL-2 ImmunoTherapY Study
Advanced Solid Tumor, Unresectable Solid Tumor
RecruitingObservational study
Pneumonia and Pleuropneumonia in Hospitalized Children
Pneumonia, Pleural Effusion
RecruitingPhase 4
VATS or Intrapleural Enzymatic Therapy for Patients With Empyema.
Empyema, Pleural, Pleural Infections
RecruitingObservational study
UNC Pleural Fluid Registry
Lung Cancer, Lung Infection
Not yet recruiting
Evaluating Antibiotic Course Upon Adequate Treatment of Empyema
Pleural Empyema
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Pleural Infection, run by University of Oxford at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 26 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Disease severity (time frame: Baseline). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07194915, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Sep 2025.